Psychogenic non-epileptic seizures (PNES) have an estimated prevalence of 33 per 100,000 individuals with a mean age of 31. It was also found to be around 80% predominantly women, based on a study that followed 367,566 people over 3 years [
1]. Signs of PNES are characterized by brief seizure-like episodes that lack the abnormal cortical activity typically seen in epileptic seizures. They are believed to stem from psychological distress, depression, and post-traumatic stress disorder (PTSD), which may manifest in physical symptoms, including convulsions, loss of consciousness, or involuntary movements [
2]. Additional causes of PNES include conditions such as syncope, complex migraines, panic attacks, and transient ischemic attacks [
3]. A diagnosis of PNES includes a thorough history and video electroencephalogram (EEG) to confirm the diagnosis [
4]. Consideration of other underlying pathologies should be carefully taken into account, as PNES and their associated signs and symptoms have been documented in the literature as being potentially linked to neoplasms or other malignancies as an early indication [
5]. Previous literature has shown an association, with 40% of patients with PNES having anti-NMDA receptor antibodies with an underlying tumor; the most common being small cell lung cancer and ovarian teratoma [
6,
7] with brain tumors also been implicated [
8]. Anti-neuronal antibodies can induce immune-mediated damage to neural tissue as a distant unintended effect of T-cell-mediated immune responses targeting the neoplasm. These unintended antibodies have the potential to induce destructive and detrimental effects on CNS neurons, resulting in inflammation characterized by the infiltration of T and B cells, as well as antibody deposition [
9,
10]. Antibodies targeting intracellular synaptic epitopes, including NMDA receptors, anti-Hu, anti-gamma-aminobutyric acid (GABA), anti-Ma2 (targeting paraneoplastic Ma antigen family like 2), Kelch-like protein 11 (KLHL11) and glutamic acid decarboxylase-65 have been detected in individuals diagnosed with paraneoplastic limbic encephalitis (PLE) [
10,
11]. These specific antibodies have also been associated with solid tumors, such as testicular tumors. KLHL11 antibodies are distinct as they have been proposed as a biomarker for paraneoplastic brainstem syndromes and directly associated with testicular seminomas [
11]. It is important to note that the absence of these antibodies does not definitively exclude the presence of a paraneoplastic syndrome [
10].
Paraneoplastic encephalitis can manifest as psychiatric symptoms, seizures, and short-term memory deficits. This condition is considered rare, with a prevalence of less than 1 per 10,000 patients [
12]. Among these cases, approximately half are associated with lung cancer and a quarter of patients are associated with testicular cancer [
12]. The specific antibody involved determines the cellular mechanisms that are impaired, giving rise to corresponding symptoms.
Glutamic acid decarboxylase 65 kDa (GAD-65) antibodies target intracellular synaptic epitopes and disrupt the GABAergic transmission. GAD autoimmunity impairs GABA synthesis by hindering the uptake of newly synthesized GABA into synaptic vesicles, resulting in reduced inhibitory GABA release. This can cause a state of neuronal hyperexcitability, which may lead to seizures involving the limbic regions [
10,
13]. However, the understanding of GABAergic transmission and its relationship to PLE is still limited. GAD-65 has also been linked to specific conditions such as cerebellar ataxia, stiff-person syndrome, and as previously mentioned PLE. Only patients with GAD-related neurological disorders will have GAD antibodies detected in cerebrospinal fluid (CSF) establishing an association with GAD antibodies and neurological disorders, no correlation between titer levels and severity have been implicated [
10,
13].
Neuroimaging should be performed to rule out brain metastases or other unusual seizure etiologies. In PLE, magnetic resonance imaging (MRI) may display T2 fluid-attenuated inversion recovery (FLAIR) signal on bilateral mesial temporal lobes [
10]. Older age, male gender, and the presence of antibodies to neuronal antigens are established risk factors for underlying malignancy [
13]. Individuals with these risk factors should undergo regular tumor screening.
The primary treatment for paraneoplastic encephalitis is dependent on the location of the antigens. Intracellular and cell surface/synapse antibodies involve the use of high-dose corticosteroids, plasmapheresis (PLEX), and intravenous immunoglobulins (IVIg), either individually or in combination. In cases where an adequate response is not observed, rituximab or cyclophosphamide is the next line of treatment [
10]. Currently, there is not enough evidence to favor one treatment over another. Oncological or surgical intervention is necessary to achieve neurological improvement in the long term of paraneoplastic neurological syndromes [
10].